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Saraswati Sukumar, BACKGROUND: Reliable intermediate biological markers for breast cancer risk, that can be easily detected in both pre-and post-menopausal women, do not exist at the present time. For more than 20 years, the ability to access breast ductal fluid through the nipple has prompted initiatives to develop a PAP-like test for breast cancer. Yields were variable, not every woman yielded fluid, and there was no assurance of obtaining samples from the entire length of the ducts. In this proposal, we will use a 1) a facile ductal lavage (DL) technique using cannulating catheters which flushes each duct to yield thousands of ductal cells. 2) a panel of markers consisting of three genes, Cyclin D2, Twist and retinoic acid receptor ß2 (RARß2), which are aberrantly hypermethylated in breast cancer cells. We will standardize the techniques using fluid from cancer patients, and then evaluate the frequency of cells positive by MSP assays in ductal lavage obtained from women with a high risk of developing breast cancer, such as patients with lobular carcinoma, patients with cancer in one breast, and those with mammographically suspicious lesions. Thus, we aim to develop a PAP test for the breast. Women with a strong family history of breast cancer may have up to an 80% risk of developing breast cancer over their lifetime. Given the rising risk, and the increasingly identifiable high-risk group, the time has come to give serious consideration to the options available to prevent breast cancer. The matter has acquired a sense of urgency in the last three years because of two seminal discoveries in the genetics of hereditary breast cancer. Individuals with a family history of breast cancer (comprising 5-10% total breast cancer cases) often carry a mutation in the breast cancer susceptibility genes BRCA1, BRCA2 or p53 and ATM are at particularly high risk of developing breast cancer at a young age. As more women test positive for mutations in BRCA1 and BRCA2, the question of how best to manage these patients becomes ever more pressing. Unless reliable and effective methods for preventing breast cancer can be devised, determining susceptibility to breast cancer may be useless and possibly even psychologically detrimental. As more breast cancer associated genes are identified, particularly among the larger population of women without a strong family history, preventive strategies with minimal side effects are clearly needed.
BODY
This proposal sought to test the radically new idea that breast cancer prevention can be achieved by selectively killing the cells that line the ducts from which the majority of malignant breast cancers arise. Multiple strategies could be applied to selectively kill breast epithelial cells. One method is to use proteins called ligand/toxin conjugates. Ligand/toxin conjugates combine their cytotoxic properties with the ability to selectively target cells carrying specific growth factor receptors. Cells that do not express the receptors remain unaffected.
We initiated experiments to determine the LD50 of the toxins when administered by the novel intraductal route in rats and the dose of toxin that will effectively ablate the mammary gland, following injection of upto 2 ug of toxin per rat, no generalized toxic effects such as weight loss or death of mammary ducts as determined by microscopic examination of sections of the mammary gland was observed, we raised the dose upto 4 ug, with no effect, neither of the two toxins was effective, suggesting that neither the egf receptor or the neu receptor was binding to the cognate human ligand linked toxin, in the face of these observations, it was clear that we needed to design a new ligand/toxin that would be lend itself to testing in rodent model systems and is then translatable to humans.
Delivery of cytotoxic proteins as a means of prevention or therapy is hampered by their size and biochemical properties. Work from Steve Dowdy's laboratory has demonstrated the efficiency of delivery of large proteins by fusing them to a 12-amino acid protein transduction domain of the HIV TAT protein. This protein transduction happens in a swift, concentrationdependent fashion is independent of receptors. Instead, it targets the lipid bilayer of the membrane of the cell. So, in theory, all mammalian cell types should be susceptible to this mode of protein Saraswati Sukumar, Ph.D. DAMD17-99-1-9242 transduction. Further the same work goes on to show internalization and expression of the same TAT protein linked to -DGAL protein in various mouse organs in vivo. The purified proteins were denatured while the injected proteins were renatured intracellularly.
Another HIV gene VPR (Viral Protein) encodes a protein which induces G2 arrest and apotosis in a variety of cell types by a direct effect on the mitochodrial permeability transition pore. Amino acids 53 to 96 of VPR encompass a basic domain that is sufficient and responsible for this apoptotic effect.
We have tried many approaches for synthesizing and purifying sufficient quantities of the TAT-VPR protein to use in animal experiments, but failed so far.
At the same time, to test the validity of the intraductal approach to prevention and therapy of breast cancer, we also initiated experiments to use simpler systems to test the efficacy of the intraductal approach to prevention and therapy using well known drugs, such as tamoxifen and doxorubicin.
We have used the well-known drug tamoxifen which has been found in clinical studies to have tumor preventive effects in women at high risk of developing breast cancer. However, liver toxicity remains a matter of grave concern in the use of tamoxifen on a long-term basis. Experiments were initiated to determine if tamoxifen (or 4-hydroxytamoxifen, its final derivative) given intraductally will provide protection against nitrosomethylurea-induced mammary carcinomas.
Sprague-Dawley rats were administered a single injection of 50mg/kg body weight of NMU. Treatment with 4-hydroxytamoxifen was initiated after 2 days. Rats were administered 50 ul of lug/ul of the drugs at weekly intervals for 4 weeks. Animals were followed up for 12 months with weekly palpations to detect tumors. Results are shown in Table 1 . the experiment was performed twice and the results are shown as cumulative numbers for the two experiments. Tamoxifen alone, and oil alone (used as a negative controls in experiment 2) had no effect, while 4-OH Tamoxifen had potent tumor preventive effects. Injection of tamoxifen s.c (positive control) was highly effective as a tumor preventive, as previously shown by others. Thus, using the metabolically active 4-OH tamoxifen given locally to the ductal cells was highly effective against development of mammary carcinomas in rats given NMU. Saraswati Sukumar, In the next series of experiments, we tested whether administration of drugs via the milk duct is effective in the elimination of established tumors. For this purpose, Doxil, which is a liposomal preparation of doxorubicin was used. NMU-induced rat mammary tumors were treated when their size reached 10mm. Fifty microliters of Doxil (2mg/ml) was administered once weekly via the duct. With the exception of one tumor which did not respond to Doxil, 11/12 tumor-bearing animals responded to the drug and remained tumor -free for over a period of 4 months of followup. All 12 tumors that were treated with control liposome continued to grow (see Table below ). Thus, the intraductal route of administration of Doxil proved very efficacious in effecting a cure. This appears to be a useful route that may prove as efficient as the systemic route but would lack the side-effects.
•Tumor size at initiation of treatment: approx.10x10x5 mm, 12 rats per group •Once weekly injection of Doxil (2mg/ml) for two weeks.
KEY RESEARCH ACCOMPLISHMENTS
-synthesized the TAT-VPR chimeric gene using oligosynthesis. Cloned the gene into an expression plasmid. Showed tumor-preventive properties of 4-hydroxytamoxifen given intraductally to Nmutreated rats -Showed tumor-therapeutic properties of Doxil, a liposomal preparation of Doxorubicin against established breast carcinomas in the rat. 
REPORTABLE OUTCOMES

CONCLUSIONS
Detailed experimentation on the in vivo effects of TGF-a-PE toxin and Heregulin/PE toxin revealed that the toxins are specific to human cells, and had no action on rat ductal cells. No toxic effects were discernible even at very high doses of 4 ug per rat. A novel toxin was designed using reagents that contain TAT domains that are internalized by all mammalian cells and the domain of VPR that causes apoptosis in cells. The chimeric protein will be injected alone and also as liposome preparations to achieve nonsurgical removal of preneoplasias as well as dividing cells in the breast. The intraductal route of injection may find uses in both prevention and therapy of breast cancer. We have shown that 4-hydroxytamoxifen can prevent the development of mammary carcinomas and Doxil can cause regression of well-established tumors in the NMU-induced mammary carcinoma model system. The work has significant potential in that it aims to develop a method of preventing breast cancer by ablating the breast epithelium that is the site of origin of breast carcinomas. The right agent to achieve this goal has not been formulated yet. Effort sare underway to design and use an agent that will be non-toxic to other cells but will kill breast epithelium. The intraductal approach to targeted and localized delivery of therapy
•Surgimimetic.
•Local administration of therapy, reducing undesirable side-effects.
•Injury and discomfort kept to a minimum.
•Repetitive delivery for maximum efficacy. Helps avoid immune system and stays active longer Liposomal formulation helps prevent toxicity.
